Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Combination neoadjuvant therapy promising in treating locally advanced cancer
December 28th, 2004
Introgen Therapeutics, Inc. (Nasdaq: INGN) reported at the 27th annual San Antonio Breast Cancer Symposium data from its Phase II trial evaluating Advexin combined with neoadjuvant chemotherapy in women with locally advanced breast cancer. Neoadjuvant treatments are administered prior to surgery and represent a novel and increasingly applied approach to make surgical tumor resections either more complete improving outcomes or less invasive facilitating breast conservation. Objective clinical responses with a greater than 50% reduction in tumor size were seen following the combined therapy in all of the patients. Complete tumor removal by subsequent...
Source: Cancer Weekly (2004-12-28)
|
